Overview

Update
Status
Sub-organisation of Qiagen
Total Equity Funding
$52M in 3 Rounds from 7 Investors
Headquarters:
Providence, Rhode Island
Description:
PrimeraDx offers multiplexed infectious disease assays that include scalable target amplification routine technology.
Founders:
Categories:
Biopharma, Chemical, Biotechnology
Website:
http://www.primeradx.com
Social:

Company Details

Update

PrimeraDx, Inc. offers multiplexed infectious disease assays. It provides Scalable Target Amplification Routine technology, which is a method for simultaneous quantitative measurement of multiple target nucleic acids. The company also offers ViraQuant, a multiplexed assay providing quantitative and simultaneous measurement of viruses; and FungiQuant Yeast and FungiQuant Mold, which are fungal panels for mycology testing. Its products are used in miRNA, DNA methylation, quantitative genotyping, gene expression, and viral load measurement applications. PrimeraDx, Inc. was founded in 2004 and is based in Mansfield, Massachusetts.

Funding Rounds (4) - $53.15M

Update
DateAmount / RoundValuationLead InvestorInvestors
Oct, 2009$20M / Series C6
Sep, 2009$1.15M / Debt Financing0
Jan, 2008$21M / Series B6
Jul, 2005$11M / Series A2

Current Team (6)

Update

Offices/Locations (1)

Update
  • Headquarters

    Providence, Rhode Island

    United States

Past Team (3)

Update

Add Acquisitions

Add Products

Add Sub Organizations

Add Competitors

Add Memberships

Add Customers

Add Partners

Add Images

Add Videos